Altair Nanotechnologies Announces New Board Member Appointment

Published on 2004-07-13. Author :
SpecialChem

RENO, NV -- Altair Nanotechnologies, Inc. (Nasdaq:ALTI),
a company engaged in developing performance materials and life science
products using its metal oxide pigment and nanomaterials technology platforms,
today announced the appointment of Dr. Michel Bazinet to its board of
directors.

"We are pleased to announce the appointment of Dr.
Michel Bazinet to our board of directors," said Altair Board Chairman
Jon Bengston. "Dr. Bazinet's extensive medical industry expertise,
coupled with his prior board of director and biotech industry experience,
will add further depth to our board, especially useful for our Life Sciences
Division."

"Altair is one of the nanotechnology leaders poised
to make a tremendous impact on the biotech industry," said Dr. Bazinet.
"I am honored to be appointed to its board, and am eager to provide
strategic guidance and leverage industry contacts to further Altair's
mission."

About Dr. Michel Bazinet

Dr. Bazinet brings extensive medical, biotech and health
sciences experience to Altair. Dr. Bazinet is Chairman & CEO of privately
held Replicor, Inc. which develop new antiviral and anticancer therapies.
Prior to his involvment with Replicor, Dr. Bazinet was the founder and
medical director of Mediconsult, a healthcare knowledge company. Mediconsult
completed its initial public offering in 1999 and was ultimately acquired
by The Cybear Group in 2001.

Dr. Bazinet, a board-certified urologist, received his
MD from Sherbrooke University. He completed his residency at McGill University,
Montreal, and has been a research fellow at Memorial Sloan-Kettering Cancer
Center, New York. Dr. Bazinet, a former assistant professor of both urology
and oncology at McGill University, is also an accomplished speaker, medical
industry author and consultant.

ALTAIR NANOTECHNOLOGIES INC.

Nanotechnology is rapidly emerging as a unique industry
sector. Altair Nanotechnologies is positioning itself through product
innovation within this emerging industry to become a leading supplier
of nanomaterial technology and nanomaterials worldwide. Altair owns a
robust proprietary technology platform for making a wide variety of nanocrystalline
materials of unique quality both economically and in large quantities.
The company is currently developing special nanomaterials with potential
applications in pharmaceuticals, batteries, thermal spray coatings, catalysts,
cosmetics, paints and environmental remediation.